RenovoRx(RNXT) - 2024 Q3 - Quarterly Results

Exhibit 99.1 RENOVO RX RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath® Delivery System in Both Direct and Commercial Partner Channels Renowned Clinical Oncology Sites Participating in Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial; Trial Moving Towards Next Interim Analysis and Full Enrollment As of September 30, 2024, the Company had $9.6 million in Cash, Suf icient to Fund Operations to ...